SK Bioscience Co Ltd (302440) - Total Liabilities
Based on the latest financial reports, SK Bioscience Co Ltd (302440) has total liabilities worth ₩847.96 Billion KRW (≈ $574.65 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 302440 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
SK Bioscience Co Ltd - Total Liabilities Trend (2018–2024)
This chart illustrates how SK Bioscience Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 302440 asset base.
SK Bioscience Co Ltd Competitors by Total Liabilities
The table below lists competitors of SK Bioscience Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhejiang Weixing New Building Materials Co Ltd
SHE:002372
|
China | CN¥1.39 Billion |
|
Intapp Inc
NASDAQ:INTA
|
USA | $384.93 Million |
|
Nations Technologies Inc
SHE:300077
|
China | CN¥2.59 Billion |
|
Zhejiang DiAn Diagnostics Co
SHE:300244
|
China | CN¥5.41 Billion |
|
Fulltech Fiber Glass
TWO:1815
|
Taiwan | NT$8.28 Billion |
|
Stock Yards Bancorp Inc
NASDAQ:SYBT
|
USA | $8.52 Billion |
|
Westshore Terminals Investment Corp
TO:WTE
|
Canada | CA$1.58 Billion |
|
Polaris Bay Group Co Ltd
SHG:600155
|
China | CN¥49.24 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down SK Bioscience Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 302440 net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SK Bioscience Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SK Bioscience Co Ltd (2018–2024)
The table below shows the annual total liabilities of SK Bioscience Co Ltd from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩821.14 Billion ≈ $556.48 Million |
+452.65% |
| 2023-12-31 | ₩148.58 Billion ≈ $100.69 Million |
-62.88% |
| 2022-12-31 | ₩400.23 Billion ≈ $271.23 Million |
-21.34% |
| 2021-12-31 | ₩508.81 Billion ≈ $344.81 Million |
+70.49% |
| 2020-12-31 | ₩298.44 Billion ≈ $202.25 Million |
+74.28% |
| 2019-12-31 | ₩171.25 Billion ≈ $116.05 Million |
-10.80% |
| 2018-12-31 | ₩191.98 Billion ≈ $130.10 Million |
-- |
About SK Bioscience Co Ltd
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the preve… Read more